Precise Length and 5-Methylcytosine Assessments of Repeat Sequences

Information

  • Research Project
  • 10254007
  • ApplicationId
    10254007
  • Core Project Number
    R43HG011561
  • Full Project Number
    1R43HG011561-01A1
  • Serial Number
    011561
  • FOA Number
    PA-20-260
  • Sub Project Id
  • Project Start Date
    5/10/2021 - 3 years ago
  • Project End Date
    4/30/2022 - 2 years ago
  • Program Officer Name
    SMITH, MICHAEL
  • Budget Start Date
    5/10/2021 - 3 years ago
  • Budget End Date
    4/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    5/10/2021 - 3 years ago

Precise Length and 5-Methylcytosine Assessments of Repeat Sequences

Project Summary During this program, Electronic BioSciences, Inc. (EBS) will develop and demonstrate a complete, end-to-end, universal methodology for repeat sequence characterization, including precise length and methylation (5- methylcytosine or 5mC) assessments. This technology will be enabled by the development and demonstration of a sequence-targeted sample and library preparation that will enable the isolation and enrichment of any repeat sequence with a known sequential context or loci for disease-specific diagnostics. Specifically, satellite DNA is comprised of sequence repeats that occur in tandem 5 or more times. Among this DNA, microsatellites have a 1?10 nucleotide (nt) repeat pattern and minisatellites have a >10-nt long repeat pattern. A specific type of satellite DNA found in coding regions of the genome are repeat expansions. Increases in repeat sequence length and epigenetic 5mC status have been correlated to a number of diseases, including Myotonic Dystrophy, Huntington?s Disease, Friedreich?s Ataxia, Fragile X, Fragile XE, Amyotrophic Lateral Sclerosis or ALS, etc., and the targeted characterization of these regions would represent a direct approach (relative to whole genome sequencing) towards clinical and point-of-care diagnostics. However, there is no technology presently available that is ideally suited for characterizing these repeat sequences as a result of read length (associated with next generation sequencing approaches) or accuracy (associated with third generation sequencing approaches), which has significantly limited the understanding of the role repeat sequences have in disease states, their diagnostic/prognostic utility, and the development of associated assays. During this Phase I SBIR program, EBS will develop and demonstrate a technology that will allow these regions to be efficiently assessed for disease state diagnostics.

IC Name
NATIONAL HUMAN GENOME RESEARCH INSTITUTE
  • Activity
    R43
  • Administering IC
    HG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    271933
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    172
  • Ed Inst. Type
  • Funding ICs
    NHGRI:271933\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ELECTRONIC BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    129852864
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921214206
  • Organization District
    UNITED STATES